How to not induce SNAs: The insufficiency of directional force

por Michirev, A., Kühne, K., Lindemann, O., Fischer, M. H., Raab, M.
Publicado 2023

Targeting the Pim kinases in multiple myeloma

por Keane, N A, Reidy, M, Natoni, A, Raab, M S, O'Dwyer, M
Publicado 2015

PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIP...

por Munshi, N., Spencer, A., Raab, M. S., Masood, A., Martinez-Prieto, M., Chu, J., Iida, S., Lonial, S., Dimopoulos, M. A.
Publicado 2022

PB1976: CRISPR-CAS9 KNOCKOUT SCREEN IDENTIFIES RNA MODIFICATION ENZYMES ESSENTIAL FOR CELL SURVIVAL IN MULTIPLE MYELOMA

por Zhao, D., Pauli, C., Rohde, C., Kienhöfer, M., Grab, A. L., Huhn, S., Raab, M., Weinhold, N., Frye, M., Müller-Tidow, C.
Publicado 2022

Coexisting multi-states in catalytic hydrogen oxidation on rhodium

por Winkler, P., Zeininger, J., Raab, M., Suchorski, Y., Steiger-Thirsfeld, A., Stöger-Pollach, M., Amati, M., Gregoratti, L., Grönbeck, H., Rupprechter, G.
Publicado 2021

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DA...

por Leypoldt, L., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M.-S., Nogai, A., Khandanpour, C., Runde, V., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M., Weisel, K.
Publicado 2022

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

por Xu, J, Pfarr, N, Endris, V, Mai, E K, Md Hanafiah, N H, Lehners, N, Penzel, R, Weichert, W, Ho, A D, Schirmacher, P, Goldschmidt, H, Andrulis, M, Raab, M S
Publicado 2017

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESS...

por Einsele, H, Cohen, AD, Delforge, M, Hillengass, J, Goldschmidt, H, Weisel, K, Raab, M-S, Scheid, C, Schecter, JM, De Braganca, KC, Varsos, H, Yeh, T-M, Wang, L, Vogel, M, Corsale, C, Akram, M, Pacaud, L, Nesheiwat, T, Agha, M, Cohen, YC
Publicado 2022

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

por Natoni, A, Smith, T A G, Keane, N, McEllistrim, C, Connolly, C, Jha, A, Andrulis, M, Ellert, E, Raab, M S, Glavey, S V, Kirkham-McCarthy, L, Kumar, S K, Locatelli-Hoops, S C, Oliva, I, Fogler, W E, Magnani, J L, O'Dwyer, M E
Publicado 2017

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES...

por Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., Varsos, H., Yeh, T.-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M., Cohen, Y. C.
Publicado 2022

P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA

por Raab, M. S., Cohen, Y. C., Schjesvold, F., Aardalen, K., Oka, A., Spencer, A., Wermke, M., Hari, P., Kaufman, J. L., Cafro, A. M., Ocio, E. M., Doki, N., Henson, K., Trabucco, G., Juif, P.-E., Chawla, R., Cotton, J., Fessehatsion, A., Fan, L., Blankenship, J., Granda, B., Lu, H., De Vita, S.
Publicado 2022

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FRO...

por Mai, E. K., Bertsch, U., Fenk, R., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Nievergall, E., Huhn, S., Kriegsmann, K., Weinhold, N., Luntz, S., Holderrried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C., Goldschmidt, H.
Publicado 2022